RN Collins (Series 3) No.5

RN Collins has written a new series (3) of 18 articles for cannabis law report on 2026 Psychedelics & Legal Issues.

This is the 5th in the series

Contact RN Collins: https://www.linkedin.com/in/rn-collins/

 

The Species Gap: State Testing Law and the Case for Molecular Authentication of Cannabis

RN Collins, M.S., JD Candidate

https://www.linkedin.com/in/rn-collins/

ABSTRACT

Cannabis testing law across legal markets requires potency, contaminant, and residual solvent testing. None of it appears to require confirmation that the botanical material in a cannabis product is actually Cannabis sativa, or that the cultivar, chemotype, or geographic origin claimed on the label is accurate. This Article examines whether the resulting authentication gap may create legal exposure under consumer protection statutes, UCC warranty doctrine, and products liability theory, and whether the gap could be addressed using a validated suite of DNA-based molecular authentication methods that have been applied to Cannabis sativa specifically and appear to be available at roughly $50 to $200 per sample at accredited agricultural testing laboratories. A five-state comparative statutory analysis suggests the gap exists uniformly across California, Colorado, Michigan, Illinois, and New York. The Article proposes a model molecular authentication framework, statutory elements, enforcement architecture, and equity accommodations, for state regulators and legislators to consider. The underlying observation driving this analysis: the relevant technology has reportedly been available and applicable to Cannabis since at least 2005, which may complicate any argument that authentication was not achievable earlier. What appears to remain is a policy choice about whether to require its use.

I. Introduction: A Species Question That State Law Does Not Appear to Answer

State cannabis law asks licensed laboratories to certify a great deal about a cannabis product, but arguably not the threshold question of what plant produced it. Every cannabis certificate of analysis (COA) reviewed for this Article certifies potency. Every COA certifies the absence of pesticides, heavy metals, and residual solvents, within the parameters tested. None of the state frameworks surveyed appear to confirm that the tested material is Cannabis sativa. None distinguish cannabis from a morphologically similar, less expensive plant material that might be substituted, deliberately or inadvertently, somewhere in the supply chain. None verify the cultivar, chemotype, or geographic origin represented on the label.

Herbal medicine adulteration is not a new problem, and it may be instructive here. It is a documented, recurring, and apparently commercially driven phenomenon that has shaped both the history of pharmacognosy and the development of modern drug quality law. The Chaudhary et al. 2014 molecular biology authentication chapter catalogues examples in detail: black pepper adulterated with dried papaya seeds; saffron extended with safflower; and Swertia chirata, a bitter tonic, substituted with the cheaper Andrographis paniculata, a substitution that appears to have caused documented adverse effects because the substitute is pharmacologically active in its own right. In each case, chemical testing of the adulterated product reportedly fell within an acceptable range for the marketed substance; only molecular authentication revealed the substitution.¹

Cannabis may sit in a comparable supply-chain vulnerability. Four questions that molecular authentication could help answer in cannabis markets, and that no state surveyed here currently appears to require answering, are:

Species identity: Is this material Cannabis sativa L.? This bears on whether the product is cannabis at all or a substituted plant material.

Chemotype classification: Is this a high-THC (Type I), balanced (Type II), or high-CBD (Type III) Cannabis? This could be relevant to hemp/marijuana border enforcement questions.

Cultivar identity: Is this the specific named cultivar represented on the label? This relates to what might be called premium product fraud.

Geographic origin: Is this cannabis from the represented region? This could bear on origin-based premium claims, which appear to command meaningful price premiums in several state markets.

This Article maps the apparent authentication gap, proposes a model statutory framework, and offers regulatory and liability analysis intended to inform state legislators and cannabis regulatory agencies as they consider whether and how to act. A note on scope: this Article develops the state statutory comparative analysis, proposes model framework text, engages the FDA and USP regulatory template literature at a technical level, and lays out a doctrinal analysis of potential liability exposure. It does not purport to resolve every open question; several of its conclusions are offered as reasonable inferences from the available literature rather than as settled determinations.

Part II describes the authentication problem and summarizes the molecular toolkit. Part III provides the comparative state statutory analysis. Part IV addresses regulatory templates potentially available for adoption. Part V considers possible liability exposure. Part VI proposes a model statute. Part VII addresses the equity dimension. Part VIII concludes.

II. The Authentication Problem: Background for Regulators

A. The Herbal Medicine Authentication Literature

The molecular authentication field in herbal medicine developed in response to a documented pattern of adulteration incidents that chemical analysis alone reportedly could not prevent or detect. The Chaudhary et al. 2014 review, a comprehensive survey of the authentication literature authored from Jamia Hamdard’s Molecular Ecology Laboratory, identifies two broad categories of adulteration: deliberate adulteration (a cheaper species intentionally mixed with or substituted for the authentic drug material) and unintentional substitution (misidentification in the supply chain, often traceable to inconsistent vernacular naming).² Both categories appear plausible in cannabis markets, though the record here is inferential rather than direct; both would currently be undetectable by any test required under the state frameworks surveyed.

The legal consequence of adulteration, where it occurs, may extend beyond individual consumer harm. It could degrade the research evidence base (studies purporting to test a specific herbal material may in fact be testing an adulterated one), could undermine the regulatory premise that a certified lot is what it claims to be, and may create liability exposure across the supply chain, a possibility explored further in Part V.

B. The Molecular Authentication Toolkit: Summary for Regulators

The following table summarizes molecular authentication methods documented in Chaudhary et al. 2014, with attention to considerations relevant to potential regulatory adoption: DNA quantity needed, equipment requirements, reproducibility, applicability to processed cannabis materials, Cannabis-specific application, and relative cost per sample.

Method	DNA Req.	Equipment	Reproducibility	Works on Processed Material?	Cannabis-Specific Application	Can ID Cultivar?	Relative Cost
RAPD	5–50 ng	Standard PCR	Moderate (conditions critical)	Yes	Species ID, population fingerprinting; documented for Cannabis	Limited	Low
AFLP	50–100 ng	PCR + polyacrylamide gel	High	Yes	Cultivar discrimination; forensic use in Cannabis	Yes	Low-Med
SSR / Microsatellites	10–100 ng	PCR + capillary electrophoresis	Very high; codominant	Yes	THCA/CBDA synthase allele typing; cultivar fingerprinting (Canter et al. 2005)	Yes	Low-Med
ISSR	5–50 ng	Standard PCR	High	Yes	Species ID; Kojoma et al. 2002 applied to Cannabis	Limited	Low
ITS / 18S rRNA Sequencing	Any	PCR + sequencing	Very high	Yes	Species ID against GenBank; Cannabis well-represented in database	No	Med
SCAR Markers	Any	Standard PCR	Very high; locus-specific	Yes	Cannabis-specific loci; designed from RAPD fragments	Possible	Low-Med
LAMP	Any	Isothermal (65°C)	High	Yes	Validated for Cannabis sativa specifically; 30-minute on-site protocol (Kitamura et al. 2018)	No	Low

For regulatory purposes, several distinctions may be worth noting, with appropriate caution: (1) the listed methods appear capable of identifying Cannabis sativa from processed materials, provided adequate DNA is present; (2) SSR microsatellite analysis and SCAR markers appear to be the most reproducible and Cannabis-specific of the methods surveyed; (3) cost per sample appears to run $50 to $200 at accredited agricultural testing laboratories, a figure that, if accurate, would be modest relative to the commercial value of authenticated product and any liability exposure associated with unauthenticated product; and (4) LAMP has been validated for Cannabis-specific authentication by Kitamura et al. (2018), a 30-minute on-site protocol targeting the THCA synthase gene, confirmed specific against 20 C. sativa strains and 50 other species.

C. What the Technology May Be Able to Confirm: A Four-Question Taxonomy

The authentication toolkit could address the four questions identified in the Introduction, each at a different level of analytical resolution. Species identity and chemotype classification appear most readily achievable and most directly relevant to existing regulatory frameworks. Cultivar identity may be achievable but would likely require a reference database of Cannabis cultivar fingerprints that most states do not yet appear to have developed. Geographic origin authentication may be achievable but would likely require population-specific marker panels analogous to those used in wine appellation enforcement, an analogy offered here for illustration rather than as a claim of direct equivalence.

III. State Cannabis Testing Law: A Comparative Analysis of the Apparent Authentication Gap

A. What State Law Appears to Require

Cannabis testing regulation is exclusively a matter of state law. A survey of five of the largest state cannabis markets by revenue, California, Colorado, Michigan, Illinois, and New York, suggests a consistent pattern: all appear to require potency, pesticide, heavy metal, microbial, mycotoxin, and residual solvent testing; none appear to require botanical identity authentication.

California: Business and Professions Code § 26100 et seq. and Cal. Code Regs. tit. 4, § 15700 et seq. require testing for cannabinoids, terpenes, residual pesticides, residual solvents, residual processing chemicals, microbial impurities, mycotoxins, heavy metals, and moisture content. No botanical identity authentication requirement was identified.³

Colorado: Colo. Code Regs. § 212-3:M1401-3 requires potency, microbial, pesticide, residual solvent, and moisture content testing. No botanical identity authentication requirement was identified.⁴

Michigan: Admin. Code R 420.301 et seq. requires testing for cannabinoid content, pesticides, heavy metals, microbials, mycotoxins, and residual solvents. No botanical identity authentication requirement was identified.⁵

Illinois: 410 ILCS 705/55-21 requires testing for potency, pesticides, heavy metals, microbials, mycotoxins, and solvents. No botanical identity authentication requirement was identified.⁶

New York: Cannabis Law § 129 and 9 N.Y.C.R.R. pt. 130 require potency, microbial, pesticide, heavy metal, mycotoxin, and residual solvent testing. No botanical identity authentication requirement was identified.⁷

The pattern appears structural and fairly consistent across the states surveyed. State cannabis testing law seems designed to answer “what is in this product” and “how much,” not “what plant produced this.” No state among those examined here appears yet to require the latter question to be answered, though this Article does not claim to have surveyed every jurisdiction.

B. The COA Adequacy Question: Legal Analysis

The COA functions as the primary instrument of quality assurance in state cannabis markets. It travels with tested lots through the supply chain from the licensed testing laboratory to the retailer to the consumer. Dispensaries appear to rely on COAs to verify that incoming product meets applicable standards; regulators appear to use COAs as an evidentiary basis for enforcement and recall decisions; consumers can typically access COA data through QR codes on product packaging.

A COA that includes no botanical identity authentication may implicitly represent that the product is what it claims to be at the species level, while in fact certifying only its chemical content. The legal significance of this omission could operate at two levels. First, the COA arguably does not certify what it may be understood to represent: a COA for a product labeled as a specific cannabis strain could be read as implicitly representing that the product contains that strain, and if the product instead contains material from a different cultivar or a non-cannabis plant, that implicit representation may be false, yet no currently required test would necessarily reveal the discrepancy. Second, a regulatory framework that relies on COAs for compliance purposes may create incentive problems when the COA itself is incomplete. An operator who substitutes less expensive bulk cannabis material for a premium named strain, while accurately reporting the chemical content of the substituted material, could be understood to have misrepresented the product at the species or cultivar level while nonetheless satisfying every currently required test, though whether that conduct would be characterized as fraud in a given case would depend on additional facts, including intent, that this Article does not attempt to resolve.

C. Track-and-Trace and the Upstream Substitution Question

Most state cannabis markets require seed-to-sale inventory tracking systems that record the physical movement of tagged cannabis through the supply chain from cultivation through retail sale. These systems appear to record batch identifiers, weights, and transfer events; they do not appear to record molecular identity information.⁸ If a cultivator were to tag a batch of hemp material as medical cannabis, or blend non-cannabis plant extract into a cannabis extract before it enters the licensed processing stream, the tracking system would presumably record the tag rather than the underlying molecular identity. On the available evidence, an upstream substitution of this kind would not be visible to the regulatory monitoring systems currently in use, though this Article has not attempted to quantify how often such substitution may actually occur.

D. The Hemp/Marijuana Border

Section 781 of the Continuing Appropriations Act 2026, Pub. L. No. 119-37 (effective November 12, 2026), amends the hemp definition to exclude cannabinoids synthesized outside the cannabis plant.⁹ For the conventional plant-derived hemp/marijuana distinction, the line remains at 0.3 percent delta-9 THC concentration on a dry weight basis under the 2018 Farm Bill. Hemp and marijuana are the same species and are morphologically indistinguishable to the eye. Marker-assisted authentication targeting THCA/CBDA synthase allele types could provide a molecular basis for classifying material as hemp-type or marijuana-type, potentially a useful enforcement tool where chemical testing results are contested, though this Article does not claim such markers would resolve every disputed case.

IV. Regulatory Templates: FDA Botanical Drug Guidance and the USP Cannabis Monograph

A. The FDA Botanical Drug Guidance as a Possible Regulatory Model

FDA’s 2016 Botanical Drug Development Guidance offers what may be the most developed federal framework for botanical product identity authentication.¹⁰ The guidance directs sponsors to characterize botanical drug substances at multiple levels of identity and addresses processed botanical materials, extracts, powders, and other forms in which macroscopic identification is not feasible, by requiring analytical authentication methods for those forms. Cannabis extracts and concentrates appear to fall within that category. The guidance’s method-neutral approach, requiring validated methods rather than prescribing specific ones, may be a reasonable model for states considering cannabis authentication regulation, though adapting a federal drug-development guidance to a state cannabis regulatory context would raise its own implementation questions that this Article does not fully resolve.

B. The USP Cannabis Monograph

The United States Pharmacopeia has developed cannabis monographs setting out quality standards for botanical identity, chemical composition, and purity.¹¹ USP monograph standards are not automatically binding on state cannabis markets, but they may offer a nationally recognized reference framework that states could adopt by cross-reference. Several states appear to have already incorporated USP standards into cannabis testing requirements for specific categories. Extending this approach to botanical identity authentication could provide technical specificity without requiring individual state agencies to develop authentication specifications independently.

V. Potential Liability Exposure: UCC, Consumer Protection, and Products Liability

A. The UCC Warranty Framework

The UCC implies a warranty of merchantability in every sale of goods by a merchant.¹² Merchantable goods must, among other things, conform to the promises or affirmations of fact made on the container or label.¹³ A cannabis product sold as a specific named cultivar with a specific claimed geographic origin arguably makes a representation about botanical identity. If molecular authentication were to demonstrate that the product does not in fact contain the represented material, a court could plausibly find that the seller breached the implied warranty of merchantability, though this Article is not aware of a reported case squarely deciding the question, and the outcome would likely depend on jurisdiction-specific warranty doctrine and the precise label language at issue.

The warranty analysis, if credited, could travel through the cannabis supply chain in the ordinary way: a retailer that purchased wholesale cannabis in reliance on a COA might have a warranty claim against its supplier if the COA accurately described chemical content but the product’s botanical identity was misrepresented; the supplier might in turn have a pass-through claim against the processor, and the processor against the cultivator. The COA functions as the instrument of reliance in this chain; a gap in the COA could, in principle, become the chain’s weakest link.

A defense premised on the argument that the COA accurately described what current testing law requires may succeed in some cases, though this is not certain. Even where that defense succeeds on the warranty question, it may not fully address the underlying representation made to the consumer. A consumer who paid a premium for a specific cultivar could be understood to have been deprived of what they paid for, regardless of whether the COA was technically compliant with applicable testing regulations, though whether a court would reach that conclusion in any particular case cannot be stated with certainty.

B. Consumer Protection Statute Claims

Every state consumer protection statute surveyed prohibits unfair or deceptive acts or practices in commerce.¹⁴ A product representation that is literally true in a narrow sense, the COA accurately describes cannabinoid content, but that may create a false impression in the mind of a reasonable consumer, for instance, that the product is a specific premium cultivar when it may not be, could be considered deceptive by omission under the FTC’s deception doctrine.¹⁵ A consumer who purchases cannabis labeled as a specific cultivar with therapeutic properties tied to that cultivar’s profile, and who pays a premium price accordingly, may have a plausible claim of material deception if the product does not in fact contain the represented material, though the strength of any such claim would turn on facts specific to the transaction.

C. Products Liability: Manufacturing Defect and Failure to Warn

Products liability claims premised on adulterated cannabis products could proceed under any of three theories: manufacturing defect (the specific unit deviated from its intended design because it contained non-cannabis or wrong-cultivar material); design defect (the production process arguably made species substitution foreseeable and difficult to detect); and failure to warn (the manufacturer arguably failed to disclose the possibility of species substitution where consumers are making health-related purchasing decisions).¹⁶

An “unavailability” defense, the argument that authentication technology was not available at the time of manufacture, may be difficult to sustain for a manufacturer operating after 2014. The Chaudhary et al. 2014 review documents the authentication toolkit and its Cannabis-specific applications in some detail, and the Canter et al. 2005 review documents Cannabis-specific molecular markers even earlier. A manufacturer unable to show that it considered molecular authentication after 2014 could face a difficult argument under the “knowability” standard of the Restatement (Third) of Torts: Products Liability, though this inference cannot be stated with the confidence that a formal judicial holding would provide, since this Article is not aware of a case applying that standard to cannabis species substitution specifically.¹⁷ At minimum, the apparent availability of Cannabis-applicable authentication methods for roughly two decades may complicate any argument that the relevant technology was not yet knowable.

VI. A Model Molecular Authentication Framework

A. Statutory Elements

The following table sets out a model framework in structured form, offered for consideration by state legislators and regulatory agencies rather than as a finished statutory text. Detail on each element follows.

Element	What It Would Require	Validated Methods	Regulatory Precedent	Implementation	Equity Note
Species identity confirmation	Processed cannabis would be confirmed as Cannabis sativa by a validated DNA-based method before retail distribution	RAPD, AFLP, SSR, ISSR, ITS sequencing, SCAR	FDA Botanical Drug Guidance (2016); USP Cannabis monograph identity provisions	Applied at processed material stage	Simplified methods could be permitted for whole-flower
Cultivar/chemotype verification	Products making cultivar-specific or chemotype-specific label claims would provide molecular evidence at a frequency set by the agency	SSR microsatellite fingerprinting; THCA/CBDA synthase allele markers	UPOV variety protection databases; agricultural crop precedent	Triggered by label claim	Cooperative compliance option for small producers
Hemp/marijuana border authentication	Cannabis material crossing the 0.3% THC threshold would be authenticated by molecular methods when chemical testing results are disputed	THCA/CBDA synthase allele-specific markers	2018 Farm Bill; Section 781 Continuing Appropriations Act 2026	Triggered on chemical testing dispute
Laboratory accreditation	Testing performed by an ISO/IEC 17025-accredited laboratory with Cannabis authentication in scope; proficiency testing participation required	Any validated method above	ISO/IEC 17025; FDA laboratory standards	Applied to all authentication testing	Shared lab infrastructure recommended for consideration
COA integration	COA would include: method used; reference database consulted; species identity confirmed or basis for deviation; cultivar/chemotype molecular evidence if claimed on label		Existing COA regulatory architecture in surveyed state markets	Applied to all COAs post-implementation
Phased implementation	An implementation period of approximately 18 months from enactment; existing licenses would not automatically satisfy the new requirements		Standard phased implementation precedent	18 months from enactment (suggested)	Particularly relevant for small producers

B. Enforcement Architecture

Authentication requirements without enforcement risk becoming a compliance formality rather than a meaningful safeguard. A model framework might reasonably include three enforcement mechanisms for state agencies to consider:

Recall authority: the state agency could be given explicit authority to recall products from retail sale when molecular authentication testing reveals species misrepresentation or undisclosed non-cannabis botanical material. Recall authority may be the most consequential of the three tools, since it could create a direct economic incentive against adulteration if the cost of a recall meaningfully exceeds the cost of authentication testing.

Civil penalties: violations of authentication requirements could be made subject to per-violation civil penalties, for instance in a range of $10,000 to $100,000, calibrated to the severity of the violation and the volume of affected product. Regulators may wish to consider treating deliberate economic adulteration, species substitution undertaken for financial gain, as warranting penalties at the higher end of any such range, along with mandatory license referral regardless of product volume.

License revocation: repeated or willful violations of authentication requirements could be made grounds for license suspension or revocation. Given the license-based enforcement architecture already used in state cannabis law generally, license revocation may be a proportionate and effective sanction for sustained or willful authentication fraud, though agencies would presumably want to reserve it for the more serious category of violations.

VII. The Equity Dimension: Authentication, Small Producers, and Market Access

Any proposal for mandatory molecular authentication should grapple with its equity implications for small cannabis producers. Laboratory accreditation, reference database access, and per-sample testing costs that may be a rounding error for large-scale producers could pose a genuine barrier for small craft cultivators, social equity licensees, and Tribal cannabis operators. The model framework in Part VI attempts to address this concern through the suggested 18-month implementation timeline and through civil penalties calibrated to violation severity and product volume rather than a flat per-violation structure, though whether these accommodations are sufficient would likely depend on how a given state’s rulemaking process implements them.

State program designers and regulatory agencies considering this framework may wish to weigh three additional design elements:

Shared laboratory resources: state cannabis regulatory agencies should consider whether public or cooperative laboratory infrastructure, similar to the extension laboratory system that supports agricultural testing in the farming sector, could provide authentication testing services to small producers at subsidized rates. The capital cost of establishing an SSR microsatellite or ITS sequencing capability at a state-supported agricultural laboratory appears modest relative to the potential market integrity benefits, though a full cost accounting is beyond the scope of this Article.

Simplified authentication tiers: a method-neutral framework could allow producers to use the least expensive validated method that meets the authentication standard. For small producers authenticating whole-flower products that have not been extracted or processed, visual botanical identification supplemented by a single ITS sequencing confirmation may be sufficient for species identity purposes, with the fuller molecular fingerprinting protocol reserved for extracted or processed materials.

Cooperative compliance: state regulators should consider permitting cooperative compliance arrangements in which a group of small producers shares a single accredited laboratory relationship and contributes to a common reference database for cultivars grown within the cooperative. This model has apparent precedents in the wine appellation, specialty coffee, and tea certification systems, and may be adaptable to the cannabis cultivar authentication context, though the analogy is imperfect and would need further development before implementation. Social equity licensees, who are disproportionately likely to be small operators without established laboratory relationships, may also be the operators most exposed to being undersold by competitors engaged in authentication fraud. A well-designed mandatory authentication requirement, paired with cooperative compliance provisions, could protect social equity licensees at least as much as it constrains them, though this Article offers that as a policy hypothesis rather than a demonstrated outcome.

VIII. Conclusion

The molecular authentication gap identified in this Article does not appear to be a technical barrier. The relevant technology exists, appears to be validated, and has reportedly been applied to Cannabis sativa specifically since at least 2005. The gap looks more like a regulatory choice, made by omission, that may leave the cannabis supply chain exposed to a category of adulteration and misrepresentation that chemical testing alone is not designed to detect.

The herbal medicine industry spent roughly three decades learning a comparable lesson through experience, eventually developing the molecular authentication toolkit that the Chaudhary et al. 2014 review documents. The cannabis industry may not need to repeat that experience in full. The tools appear to exist. The regulatory frameworks, FDA botanical drug guidance, USP Cannabis monograph standards, could provide a template for adoption, with adaptation. The comparative state analysis in Part III suggests the gap exists uniformly across the major cannabis markets surveyed here. The model framework in Part VI offers specific elements, enforcement architecture, and equity accommodations for states to consider as they weigh whether to close it.

What appears to remain is the political will to ask the species identity question that current law, as surveyed here, does not require anyone to answer. This Article is offered as one contribution toward that inquiry.

ENDNOTES

1. Chaudhary, S.K. et al., Molecular Authentication of Medicinal Plants, in Current Trends in Medicinal Botany (2014) (documenting deliberate adulteration, unintentional substitution, and documented cases of consumer harm resulting from species misidentification in herbal supply chains).

1. Id.

1. Cal. Bus. & Prof. Code § 26100 et seq. (West 2023), https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?sectionNum=26100.&lawCode=BPC; Cal. Code Regs. tit. 4, § 15700 et seq. (2023).

1. Colo. Code Regs. § 212-3:M1401-3 (2023), https://www.sos.state.co.us/CCR/GenerateRulePdf.do?ruleVersionId=11174&fileName=1 CCR 212-3.

1. Mich. Admin. Code R 420.301 et seq. (2023), https://www.michigan.gov/cra/industry-information/admin-rules.

1. Cannabis Regulation and Tax Act, 410 ILCS 705/55-21 (2023), https://www.ilga.gov/legislation/ilcs/ilcs4.asp?ActID=3992&SeqStart=8200000&SeqEnd=8600000.

1. N.Y. Cannabis Law § 129 (McKinney 2023), https://www.nysenate.gov/legislation/laws/CAN/129; 9 N.Y.C.R.R. pt. 130 (2023).

1. See generally state METRC and BioTrack documentation.

1. Continuing Appropriations Act 2026, Pub. L. No. 119-37, § 781 (enacted Nov. 12, 2025, effective Nov. 12, 2026).

1. FDA, Botanical Drug Development: Guidance for Industry (Dec. 2016), https://www.fda.gov/media/93113/download.

1. United States Pharmacopeia, Cannabis monographs, https://www.usp.org/dietary-supplements/cannabis.

1. U.C.C. § 2-314(1) (Am. L. Inst. & Unif. L. Comm’n 2022), https://www.law.cornell.edu/ucc/2/2-314.

1. U.C.C. § 2-314(2)(f) (Am. L. Inst. & Unif. L. Comm’n 2022) (merchantable goods must “conform to the promises or affirmations of fact made on the container or label if any”), https://www.law.cornell.edu/ucc/2/2-314.

1. See, e.g., Cal. Bus. & Prof. Code § 17200 (West 2023), https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?sectionNum=17200.&lawCode=BPC; N.Y. Gen. Bus. Law § 349 (McKinney 2023), https://www.nysenate.gov/legislation/laws/GBS/349.

1. FTC Policy Statement on Deception (Oct. 14, 1983), appended to In re Cliffdale Assocs., Inc., 103 F.T.C. 110, 174 (1984), https://www.ftc.gov/legal-library/browse/ftc-policy-statement-deception.

1. See Restatement (Third) of Torts: Products Liability §§ 2(a), 2(b), 2(c) (Am. L. Inst. 1998).

1. Restatement (Third) of Torts: Products Liability § 10 cmt. b (Am. L. Inst. 1998) (discussing “knowability” standard; technology reportedly available since Canter et al. 2005 and Chaudhary et al. 2014, which may complicate an unavailability defense for a manufacturer operating after 2014).

1. Yuki Kitamura et al., Improved On-Site Protocol for the DNA-Based Species Identification of Cannabis sativa by Loop-Mediated Isothermal Amplification, 41 Biol. Pharm. Bull. 1214 (2018), https://pubmed.ncbi.nlm.nih.gov/30068883/ (documenting a validated 30-minute on-site LAMP protocol targeting the THCA synthase gene, specific against 20 C. sativa strains and 50 other species).